Amgen Inc (BUE:AMGN)
ARS 10400 250 (2.46%) Market Cap: 151.64 Til Enterprise Value: 203.40 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 57/100

Amgen Inc at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 04:35PM GMT
Release Date Price: ARS6548.5 (-0.78%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Okay. Welcome, everyone. My name is Geoff Meacham. I'm the senior biopharma analyst here at BofA, and welcoming you to the London Health Care Conference. I also have asked Aspen Mori from my team with me as well. There are questions via the Veracast system, so feel free to log those in. And we are thrilled today to have Amgen presenting. And speaking on behalf of Amgen, we have CFO, Peter Griffith. We have to -- also have Arvind Sood from the IR team. Welcome, guys.

Peter H. Griffith
Amgen Inc. - Executive VP & CFO

Thank you, Geoff.

Arvind Sood
Amgen Inc. - VP of IR

Thank you.

Peter H. Griffith
Amgen Inc. - Executive VP & CFO

Thank you to AML, too. Thank you for having us.

Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst

Of course, yes. So you guys are going to go through some slides first.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot